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heterogeneity should be conducted, and approaches illustrated here can be 
useful to explore heterogeneity. Further evaluation of the value of patient-level 
as opposed to summary-level data in heterogeneity assessment is needed.  
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OBJECTIVES: The defining characteristics of a disease condition are the same 
across all countries. Therefore, we hypothesize that when assessing a new 
treatment, via a clinical trial, we would expect different countries to value the 
same outcomes irrespective of where the trial was completed. We chose three 
disease conditions that are identified by exact biomarkers to test this hypothesis. 
METHODS: We collected all open, actively enrolling, phase III drug studies from 
www.clinicaltrials.gov for Multiple Sclerosis, Hepatitis C, and HIV. After 
eliminating non-interventional studies and studies with missing information, we 
were left with 39 Multiple Sclerosis, 33 HIV, and 40 Hepatitis C trials. We defined 
three study locations: “U.S. only,” “ex-U.S. only,” and “U.S. and ex-U.S.” Among 
Multiple Sclerosis studies, 13 were U.S.-only, 15 ex-U.S. only, and 11 were U.S. 
and ex-U.S. Among HIV studies, 3 were U.S.-only, 19 ex-U.S. only, and 11 were 
U.S. and ex-U.S. Among Hepatitis C studies none were U.S. only, 23 ex-U.S., and 
17 were U.S. and ex-U.S. Fisher’s exact test was used to examine associations 
between study locations and types of clinical trial outcomes measured. 
RESULTS: We found no statistically significant differences in the outcomes 
evaluated by Multiple Sclerosis studies or HIV studies. Four of the 11 Hepatitis C 
outcome categories evaluated different outcomes depending on location: 
Sustained Virologic Response Week 12 (p-value 0.0011), Laboratory (p-value 
0.0525), AEs (p-value 0.0235), and Safety (p-value 0.0227). CONCLUSIONS: Our 
results support our hypothesis for two of the three conditions we examined, 
Multiple Sclerosis and HIV. However, for Hepatitis C, we found that clinical trials 
outcomes differ by location. The recent surge in development in Hepatitis C 
drugs may explain the discrepancy; however, further research and more data is 
needed.  
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OBJECTIVES: Network meta-analysis of published survival data are often based 
on the reported hazard ratio. In this paper we illustrate the value of 
reconstructing data from published Kaplan-Meier curves to perform network 
meta-analysis. METHODS: Published Kaplan-Meier survival curves of trials 
evaluating different interventions for non-small-cell lung cancer were digitally 
scanned. Next, a dataset was created with for each treatment of each trial the 
number of events and number of patients at risk for multiple short time intervals 
over the complete follow-up period. Two types of network meta-analyses were 
performed: 1) For each publication for which no hazard ratio was reported, a 
hazard ratio was estimated based on the scanned curves. Subsequently, all 
hazard ratios of all trials were synthesized with a network meta-analysis model 
assuming a constant hazard ratio (2-step approach); 2) A network meta-analysis 
of the constructed data of the Kaplan-Meier curves of all trials was performed (1-
step approach). RESULTS: The 1-step approach showed that the assumption of a 
constant hazard ratio was not valid for the used dataset. The results of the 1-step 
network meta-analysis could be presented as pooled parametric survival curves. 
CONCLUSIONS: Reconstructing data from published Kaplan-Meier curves allows 
for the inclusion of all relevant studies in a network meta-analysis, even if 
hazard ratios are not reported. Furthermore, it allows for network meta-analysis 
models that do not rely on the assumption of a constant hazard ratio, which 
have great value for cost-effectiveness models.  
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OBJECTIVES: In the last decade, network meta-analysis (mixed treatment 
comparison meta-analysis) has been introduced as a generalization of pair-wise 
meta-analysis. Many randomized controlled trials (RCTs) report treatment effect 
estimates for the outcomes of interest at multiple time points. In this paper we 
compare different methods for network meta-analysis of repeated measures. 
METHODS: Different network meta-analysis models for the synthesis of study 
level data of RCTs evaluating interventions for osteoarthritis were compared: 
separate network meta-analyses per time point; models assuming a linear 
development of treatment effects over time; network meta-analysis models with 
fractional polynomials; and network meta-analysis with splines. All analyses 
were performed in a Bayesian framework. RESULTS: The primary limitation of 
multiple network meta-analyses of study level data by time point was  
the inconsistency in the used evidence base for each time point. Of the models 
that estimate a relationship between outcome and time, fractional polynomials  
had an advantage over splines for the current dataset because the former  
model resulted in more stable parameter estimates and still  
provided sufficient fit to the data. CONCLUSIONS: To understand  
treatment effects over time, reported treatment effects of RCTs need to be 
synthesized simultaneously. Network meta-analysis of longitudinal study level 
data with second order fractional polynomials are a very useful approach to 
evaluate trends of treatment effects over time when there is not too much 
variation in treatment effects from one time point to the next. An additional 
advantage is that the methodology can handle differences in follow-up time 
across trials.  
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OBJECTIVES: 1) To Study the effect of L-carnitine supplementation on behavioral 
symptoms in autistic children; 2) Study the effect of l-Carnitine supplementation 
on Acyl-Carnitine profile of Autistic children; 3) Detect possible correlation 
between the blood Carnitine status and Autistic behavior; and 4) Tolerability 
assessment of l-carnitine supplementation. METHODS: Thirty children 
diagnosed with autism were randomly assigned to receive (100 mg/kg 
bodyweight/day) of liquid l-carnitine (n=16) or placebo (n=14) for 6 months. 
Measurements included changes in childhood autism rating scale (CARS) form 
and free and total carnitine levels using tandem mass spectrometry. RESULTS: 
Results showed significant improvement in CARS scores (P-groups <0.001) and  
(P-overtime= 0.006), with statistically significant differences in free carnitine 
levels (P=0.027) and total carnitine levels (P=0.036 ) . There was no correlation 
between baseline free and total carnitine levels with changes in CARS scores 
from zero to 6 months (r > 0.5 , P> 0.05) and generally L-carnitine therapy was 
well tolerated. In conclusion, L-carnitine therapy (100 mg/kg-bodyweight/day) 
administered for 6 months significantly improved the autism severity, but 
subsequent studies are recommended. CONCLUSIONS: 1) Significant differences 
were found in free and total carnitine levels after therapy; 2) Clinically, L-
carnitine supplementation improves autism severity; 3) L-carnitine therapy was 
well tolerated; and 4) L-carnitine supplements may be given as part of autism 
treatment regimen.  
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OBJECTIVES: Post-authorization interventional clinical trials (CT) and non-
interventional clinical studies (NIS) are increasingly used to evaluate safety and 
other outcomes in real-world settings. Previously, NIS clinical study report (CSR) 
templates used International Society for Pharmacoepidemiology (ISPE; 
www.pharmacoepi.org) reporting guidelines and/or were modified from 
International Conference on Harmonisation (ICH) E3 guidelines. Resulting CSR 
templates may not have contained adequate instructions to develop CSRs for 
regulatory review and subsequent corresponding manuscripts. We reviewed 
various published documents and developed robust NIS CSR templates for use in 
regulatory submission. METHODS: Guidelines reviewed included ISPE (based on 
FDA guidance and EU documents) and Guideline on Good Pharmacovigilance 
Practices – module VIII (www.ema.europa.eu), which describes post-
authorization safety studies (PASS) and updated CSR guidelines, following 
implementation of revised pharmacovigilance legislation in July 2012. For NIS 
manuscripts, STROBE (STrengthening the Reporting of oBservational studies in 
Epidemiology) guidelines (www.strobe-statement.org) were reviewed. We also 
reviewed other NIS-related documents, as well as interventional CT-related 
documents, including ICH CSR guidelines and CONSORT (CONsolidated 
Standards of Reporting Trials) or other design-specific guidelines (www.equator-
network.org) for writing corresponding manuscripts. Additional instructional 
and preferred/optional text was developed for the templates. RESULTS: Overall, 
PASS guidelines provided additional NIS details and were aligned with most 
regulatory sections common in ISPE and aligned closely with STROBE 
statements. ISPE guidelines provided few details for CSR template development. 
Other guidelines and a literature review provided additional CSR template text 
and the inclusion of STROBE–based text supported development of manuscripts. 
By utilizing multiple document sources, new templates were developed that 
contained improved instructions and text while meeting regulatory 
requirements. Furthermore, decision trees were included to support the 
numerous types of NIS study designs. CONCLUSIONS: By aligning CSR guidelines 
with design-specific publication guidelines, template quality was improved for 
regulatory submissions and authors could easily identify important report 
content when writing peer-reviewed publications.  
 
PRM16  
CLINICAL OUTCOME OF FLOUORO-2,DEOXY-GLUCOSE POSITRON EMMISSION 
TOMOGRAPHY/ COMPUTED TOMOGRAPHY [ FDG PET/CT] IN BREAST CANCER 
PATIENTS- STUDY BASED ON ITS REFFERAL PATTERN  
Gupta SK1, Dougall P2, Gupta P3 
1DIPSAR, University of Delhi, NEW DELHI, India, 2Max Super Specialty Hospital, New Delhi, 
India, 3DIPSAR, New Delhi, India  
OBJECTIVES: To assess the referral patterns and impact for FDG PET/CT for 
treatment management, and to determine the most common metastatic sites in 
breast cancer patients. METHODS: Retrospective analysis was performed on 
2,500 scans reported in Max hospital from November 2009 to March 2012, scans 
for breast cancer patients were separated out (500 scans). Medical records of 122 
consecutive breast cancer patients were retrospectively reviewed. Referral 
categories for PET/CT in breast cancer patients were: Diagnosis, Staging, 
Restaging, Early treatment response evaluation (after 3 cycles of chemotherapy), 
late treatment response evaluation (after 6 cycles of chemotherapy), and 
Radiation therapy response evaluation. RESULTS: PET/CT was mostly used for 
